Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

In their January 2011 Drug Safety Update, the UK MHRA warns that treatment with either bevacizumab [Avastin] or sunitinib [Sutent]

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Bevacizumab and sunitinib: risk of osteonecrosis of the jaw. Drug Safety Update 4: [3 pages], No. 6, Jan 2011

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    In their January 2011 Drug Safety Update, the UK MHRA warns that treatment with either bevacizumab [Avastin] or sunitinib [Sutent]. React. Wkly. 1335, 3 (2011). https://doi.org/10.2165/00128415-201113350-00007

    Download citation

    Keywords

    • Public Health
    • Bevacizumab
    • Bisphosphonates
    • Sunitinib
    • Osteonecrosis